TNBC, the breast cancer phenotype associated with the worst prognosis [13,14,15], does not benefit from molecularly targeted therapy, such as hormone treatment or anti-HER-2neu therapy, because these tumors lack the expression of estrogen and progesterone receptors and epidermal growth factor receptor 2 (HER-2neu). This evidence concerns the gene PGR and breast cancer.